The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings
Dormant, disseminated tumor cells (DTCs) are thought to be the source of breast cancer metastases several years or even decades after initial treatment. To date, a selective therapy that leads to their elimination has not been discovered. While dormant DTCs resist chemotherapy, evidence suggests tha...
Main Authors: | Ryann E. Shor, Jinxiang Dai, Sun‐Young Lee, Laura Pisarsky, Irina Matei, Serena Lucotti, David Lyden, Mina J. Bissell, Cyrus M. Ghajar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13031 |
Similar Items
-
Design, Synthesis and Phenotypic Profiling of Simplified Gedatolisib Analogues
by: Caroline Marques Xavier Costa, et al.
Published: (2023-01-01) -
ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells
by: Changfu Liu, et al.
Published: (2021-02-01) -
Comprehensive RNAseq analysis reveals PIK3CD promotes glioblastoma tumorigenesis by mediating PI3K-Akt signaling pathway
by: Zulfikar Azam, et al.
Published: (2020-01-01) -
A Lung Organotypic Coculture Reveals a Role for TFEB-Lysosomal Axis in the Survival of Disseminated Dormant Cancer Cells
by: Manuela Zangrossi, et al.
Published: (2021-02-01) -
Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
by: Cha Len Lee, et al.
Published: (2023-12-01)